Compare OCGN & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OCGN | IMRX |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United States | United States |
| Employees | N/A | 53 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 387.3M | 340.7M |
| IPO Year | 2014 | 2021 |
| Metric | OCGN | IMRX |
|---|---|---|
| Price | $1.78 | $5.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $9.75 | ★ $17.20 |
| AVG Volume (30 Days) | ★ 10.7M | 802.2K |
| Earning Date | 03-04-2026 | 03-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 31.58 | ★ 37.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,980.89 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $1.10 |
| 52 Week High | $2.73 | $10.08 |
| Indicator | OCGN | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.77 | 53.43 |
| Support Level | $1.47 | $4.83 |
| Resistance Level | $2.73 | $5.36 |
| Average True Range (ATR) | 0.23 | 0.29 |
| MACD | -0.07 | 0.00 |
| Stochastic Oscillator | 8.04 | 57.77 |
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.